AstraZeneca/Daiichi Sankyo Line Up More Enhertu Indications

Promising Phase II Data In Multiple Tumor Types

The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial. 

Dart
Enhertu on target for more indications • Source: Shutterstock

AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu is on the rise following a string of regulatory approvals for breast, lung and gastric cancers but new data suggests that the antibody-drug conjugate (ADC) could be an effective treatment for a wide range of other HER2-expressing tumors.

The UK major says that high-level results of a mid-stage trial of Enhertu (trastuzumab deruxtecan) met the prespecified target for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category